Full Press Release Details
PORTLAND, ME--(Marketwire - November 4, 2008) - ImmuCell Corporation (NASDAQ: ICCC) today
announced the results of its operations for the three and nine-month
periods ended September 30, 2008.
For the three-month period ended September 30, 2008, product sales
decreased by 6%, or $59,000, to $924,000 in comparison to the same period
in 2007. For the nine-month period ended September 30, 2008, product sales
increased by 3%, or $99,000, to $3,381,000 in comparison to the same period
"A 2% increase in sales of our lead product, First Defense , during the
nine-month period ended September 30, 2008, is less than we had budgeted
but is better than a decline in this very tough economic environment,"
commented Michael F. Brigham, President and CEO.
Product development expenses decreased by 18%, or $104,000, to $485,000
during the three-month period ended September 30, 2008 in comparison to the
same period in 2007. During the three-month period ended September 30,
2007, product development expenses included approximately $329,000 in
non-cash amortization expense pertaining to a technology asset that was
written off during the third quarter of 2007. Product development expenses
increased by 8%, or $91,000, to $1,241,000 during the nine-month period
ended September 30, 2008 in comparison to the same period in 2007. During
the nine-month period ended September 30, 2007, product development
expenses included approximately $439,000 in non-cash amortization expense
pertaining to that technology asset.
The net loss was $(268,000) (or $(0.09) per share) during the three-month
period ended September 30, 2008 in contrast to net income of $354,000 (or
$0.12 per share) during the same period in 2007. Technology licensing
revenue decreased by $931,000 (or 100%), as the result of the product
development and marketing agreement that was terminated during the third
The net loss was $(429,000) (or $(0.15) per share) during the nine-month
period ended September 30, 2008 in contrast to net income of $590,000 (or
$0.19 per diluted share) during the same period in 2007. Technology
licensing revenue decreased by $1,248,000 (or 100%), as the result of the
product development and marketing agreement that was terminated during the
third quarter of 2007.
"Our net loss is in line with our earlier expectations and primarily
reflects our strategic decision to make a significant and controlled
investment in the development of Mast Out ," commented Dr. Joseph H.
Crabb, Vice President and Chief Scientific Officer. "We have enrolled
approximately 40% of the qualified cases required to reach our targeted
size for the pivotal effectiveness study."
Cash, cash equivalents and short-term investments decreased by 6%, or
$336,000, to $5,076,000 at September 30, 2008 as compared to $5,412,000 at
December 31, 2007. Stockholders' equity decreased by 3%, or $345,000, to
$9,712,000 at September 30, 2008 as compared to $10,057,000 at December 31,
2007. The Company had 2,895,000 shares of common stock outstanding as of
(Unaudited) (Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
---------------------- ---------------------
(In thousands, except per
share amounts) 2008 2007 2008 2007
---------- ---------- --------- ----------
Product Sales $ 924 $ 983 $ 3,381 $ 3,283
Other Revenues -- 949 5 1,283
---------- ---------- --------- ----------
Total Revenues 924 1,932 3,386 4,566
Product costs 621 476 1,882 1,618
Product development expenses 485 589 1,241 1,149
Selling, general and
administrative expenses 368 329 1,139 984
---------- ---------- --------- ----------
Total costs and expenses 1,474 1,394 4,262 3,751
---------- ---------- --------- ----------
Net operating (loss) income (550) 538 (876) 815
Interest and other income 50 67 166 214
---------- ---------- --------- ----------
(Loss) income before income
taxes (500) 605 (710) 1,029
Income tax (benefit) expense (232) 251 (281) 439
---------- ---------- --------- ----------
Net (loss) income $ (268) $ 354 $ (429) $ 590
========== ========== ========= ==========
Net (loss) income per common
Basic $ (0.09) $ 0.12 $ (0.15) $ 0.20
Diluted $ (0.09) $ 0.12 $ (0.15) $ 0.19
========== ========== ========= ==========
Weighted average common shares
Basic 2,895 2,897 2,893 2,899
Diluted 2,895 3,013 2,893 3,049
At September 30, At December 31,
(In thousands) 2008 2007
-------------------- --------------------
Cash, cash equivalents and
short-term investments $ 5,076 $ 5,412
Total assets 10,190 10,412
Net working capital 6,368 6,710
Stockholders' equity $ 9,712 $ 10,057
ImmuCell Corporation is a biotechnology company that is developing,
manufacturing and selling products that improve animal health and
productivity in the dairy and beef industries. Press releases and other
information about the Company are available at http://www.immucell.com.
Contact Information: Contact:
President and Chief Executive Officer
(207) 878-2770 Ext. 3106